RT Journal Article
SR Electronic
T1 Quantitative detection of SARS-CoV-2 B.1.1.7 variant in wastewater by allele-specific RT-qPCR
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.28.21254404
DO 10.1101/2021.03.28.21254404
A1 Lee, Wei Lin
A1 McElroy, Kyle A
A1 Armas, Federica
A1 Imakaev, Maxim
A1 Gu, Xiaoqiong
A1 Duvallet, Claire
A1 Chandra, Franciscus
A1 Chen, Hongjie
A1 Leifels, Mats
A1 Mendola, Samuel
A1 Floyd-O’Sullivan, Róisín
A1 Powell, Morgan M
A1 Wilson, Shane T
A1 Wu, Fuqing
A1 Xiao, Amy
A1 Moniz, Katya
A1 Ghaeli, Newsha
A1 Matus, Mariana
A1 Thompson, Janelle
A1 Alm, Eric J
YR 2021
UL http://medrxiv.org/content/early/2021/03/29/2021.03.28.21254404.abstract
AB Wastewater-based epidemiology (WBE) has emerged as a critical public health tool in tracking the SARS-CoV-2 epidemic. Monitoring SARS-CoV-2 variants of concern in wastewater has to-date relied on genomic sequencing, which lacks sensitivity necessary to detect low variant abundances in diluted and mixed wastewater samples. Here, we develop and present an open-source method based on allele specific RT-qPCR (AS RT-qPCR) that detects and quantifies the B.1.1.7 variant, targeting spike protein mutations at three independent genomic loci highly predictive of B.1.1.7 (HV69/70del, Y144del, and A570D). Our assays can reliably detect and quantify low levels of B.1.1.7 with low cross-reactivity, and at variant proportions between 0.1% and 1% in a background of mixed SARS-CoV-2. Applying our method to wastewater samples from the United States, we track B.1.1.7 occurrence over time in 19 communities. AS RT-qPCR results align with clinical trends, and summation of B.1.1.7 and wild-type sequences quantified by our assays strongly correlate with SARS-CoV-2 levels indicated by the US CDC N1/N2 assay. This work paves the path for rapid inexpensive surveillance of B.1.1.7 and other SARS-CoV-2 variants in wastewater.Competing Interest StatementMM and NG are cofounders of Biobot Analytics, Inc. EJA is advisor to Biobot Analytics, Inc. KAM, MI, CD, SM, RF, MMP, and STW are employees at Biobot Analytics, and all these authors hold shares in the company.Funding StatementThis research is supported by the National Research Foundation, Prime Minister's Office, Singapore under its Campus for Research Excellence and Technological Enterprise (CREATE) program, the Intra-CREATE Thematic Grant (Cities) grant NRF2019-THE001-0003a to JT and EJA and funding from the Singapore Ministry of Education and National Research Foundation through an RCE award to Singapore Centre for Environmental Life Sciences Engineering (SCELSE) to JT. This work was also supported by funds from the Massachusetts Consortium on Pathogen Readiness and China Evergrande Group to MM and EJA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRBs are required for wastewater work.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSource data will be made available upon request